-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: Lianhua Qing plague products are mainly used for cold, influenza-related diseases treatment.
recently, Shijiazhuang Yingling Pharmaceutical Co., Ltd. received the Philippine Food and Drug Administration approved the issuance of the drug registration certificate, approved the company's drug Lianhua Qing pestist capsules in line with the Philippine traditional plant medicine standardregistration.
Lianhua Qing plague products for the leading products of Ling Pharmaceutical, the national basic drug catalog and the national medical insurance catalog (Class A) varieties, mainly used for the treatment of cold, influenza-related diseases.
Lianhua Qing plague products have been repeatedly included in the National Health And Health Administration, the State Administration of Traditional Chinese Medicine in the cold, influenza-related diseases diagnosis and treatment program.
2020 Lianhua qing capsules/particles are listed as recommended for the "New Coronary Virus Infection Pneumonia Treatment Program" (trial version 4/5/6/7) jointly issued by the National Health And Health Administration and the State Administration of Traditional Chinese Medicine.
April 12, 2020, the State Drug Administration approved lianhua clear plague capsules/particles to add a "new coronavirus pneumonia light, common type" of new indications on the basis of the original approved indications.
2019, Lianhua Qing's products achieved operating income of RMB 1,703 million, accounting for 29.24% of the total operating income of Yiling Pharmaceuticals.
the first quarter of 2020, Lianhua Qing's products achieved operating income of RMB 1,542 million, accounting for 66.07 percent of the company's total operating income.
so far, Lianhua Qing capsules in China's Hong Kong, Macao and Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, Laos, respectively, in the "Chinese medicine", "drugs", "plant medicine", "natural health products," "food supplements," "modern plant medicine", "natural medicine" and other status registered to obtain a listing license.
.